Many governments in the World have been promoting a holistic approach to leading a healthy lifestyle, which includes being physically active, maintaining a balanced diet, and having regular medical screening to keep citizens healthy. However, many people, even medical professionals, are still determining what to screen. The Health Promotion Board, an agency under the Ministry of Health Singapore, provides health screening recommendations. Their offers are age-based. For example, if one is above the age of 50, this Board recommends checking for diabetes mellitus, lipid profile, blood pressure, and colorectal cancer. [1] However, many people or citizens may be surprised that the recommended screening tests are so limited. The reason for such a short list of recommended diseases to screen for is that many diseases, especially cancer, cannot be screened. Furthermore, screening for cancers such as prostate cancer, stomach cancer, and pancreatic cancer is not well accepted. According to the Health Promotion Board, the only cancers that can be successfully screened are colorectal, cervical, and breast. Even then, screening for breast cancer is not without controversies, especially with the current medical advancement in treating breast cancer. [1] Despite these recommendations, many medical professionals still screen for malignancies like gastric cancer using carbohydrate antigen (CA) 72-4, especially in Chinese, as part of a routine health screening. This is understandable, as gastric cancer is aggressive and fatal. It is also the fifth most common cancer in the World, with one million new cases reported each year, half of them from China. [2] The main dilemma facing clinicians, especially specialists, is what to do when this group of asymptomatic healthy population is referred to them for an incidental finding of raised CA 72-4. Do they observe since these people are asymptomatic, or do they investigate, as CA 72-4 has been reported to have a high specificity of 92.8 % for gastric cancer? [3] If they do investigate, do they perform an esophagogastroduodenoscopy (EGD), or do they investigate further if the EGD is unremarkable as CA 72-4 is also expressed in human adenocarcinomas like colonic, breast, ovarian, cervical, endometrial and lung malignancies. [4-8] To decide on the best management